PAREXEL to Present at Citi Global Healthcare Conference; Impact on Pharma Industry Discussed in New Study Print
By Staff and Wire Reports   
Monday, 20 February 2012 20:01
Below is a look at some of the headlines for companies that made news in the healthcare sector on February 20, 2012.

PAREXEL International Corporation (NASDAQ: PRXL) announced it will be presenting at the Citi Global Healthcare Conference in New York. James Winschel, Sr. Vice President and Chief Financial Officer will be making a presentation on PAREXEL at 3:00 p.m. ET on Tuesday, February 28, 2012.

A live webcast of the presentation will be available through the "Investors" section of PAREXEL's website at www.PAREXEL.com in the Upcoming Events portion of the main page, and a replay of the presentation will be available on the website until May 28, 2012.


=====


While the Food and Drug Administration (FDA) has recently clamped down on what pharma can say about their drugs and introduced stringent new transparency rules, the same laws do not apply to academic detailers. And with the ever increasing use of academic detailing in the US, where the Agency for Healthcare Research and Quality (AHRQ) has poured almost USD 30 million into the practice, there are rising concerns over the underlying motivation for its use, considering tighter public drug budgets.

New research study “Academic Detailing: Pharma Fights Back” elaborated by FirstWord examines the impact the practice of academic detailing is having on the pharmaceutical industry. It questions not only the different rules for the industry and academic detailers, but under what conditions the approach works best and how pharma can fashion its response depending on whether the messages are favourable or not. The report also reveals new marketing approaches like changing compensation structures for sales staff and the increasing use of MSL teams, as well as offers true and unbiased insight into how pharma can keep up with what prescribers are hearing and how it can be managed.



Also Monday:



Dako, a world leading independent cancer diagnostic supplier with 45 years of experience in pathology, announced today that it has entered into a new collaboration agreement with Amgen Inc. (NASDAQ: AMGN) on the development of a diagnostic test for an Amgen cancer drug candidate in clinical development.

Baxter International Inc. (NYSE: BAX)
announced today that it will present at the Cowen and Company 32nd Annual Healthcare Conference on Monday, March 5, 2012, at 1:30 p.m. ET.

Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced that company management will present at investor conferences during February and March to discuss the company’s business activities, financial outlook, and current news.

Emergent BioSolutions Inc. (NYSE: EBS) announced today that the company will be webcasting its corporate overview presentation at the 32nd Annual Cowen and Company Health Care Conference in Boston on Monday, March 5, 2012 at 3:40 PM Eastern.

Exact Sciences Corp. (Nasdaq: EXAS), a molecular diagnostics company focused on colorectal cancer, today announced the appointment of Laura S. Stoltenberg as chief commercial officer.

GE Healthcare, the healthcare business of GE (NYSE: GE) announced today that it is to begin offering Fast Trak training in a state-of-the-art facility at the School of Life Sciences and Chemical Technology, Ngee Ann Polytechnic, Singapore.

Medistem Inc. (PINKSHEETS: MEDS) announced today initiation of joint efforts with the Chinese conglomerate, Shanghai Jia Fu Medical Apparatus Inc, in developing the Endometrial Regenerative Cell (ERC) "universal donor" stem cell product for the Chinese market.



"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus